Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTEGRATED BIOPHARMA INCINBP · Entity 8227 | Co-Chief Executive Officer · 10% owner | December 09, 2025 | December 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTEGRATED BIOPHARMA INC
Report date December 09, 2025 · Filed December 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2035-12-09 | Direct | 140,000 |
Reported balance
After 2025-12-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-09 · Grant · Acquired 140,000 · Balance 140,000 F1: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on December 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on December 9, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2025 Filed Dec 10, 2025 22:25 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001064900-25-000002 · primary_doc.xml · derivative · entry 1 RIVA SHEPPARD · CIK 0001064900 · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2035-12-09 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on December 9, 2026. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:57 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | Disposition to issuerStock Option (Right to Buy) · Derivative | 144,445 | $0.00 Strike: $0.09 | $0.00 |
DisclosureSEC source: 0001345281-25-000004 · primary_doc.xml · derivative · entry 2 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 144,445 shares Expires 2025-06-02 F2 · derivative.exercise_date: 81,945 of the options became exercisable on June 2, 2015 and the remaining 62,500 became exercisable in three equal annual installments beginning on June 2, 2016. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:57 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantCommon Stock | 144,445 | $0.09 | $13,000.05 |
DisclosureSEC source: 0001345281-25-000004 · primary_doc.xml · nonDerivative · entry 1 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,473,467 F1 · kind: 144,445 common stock shares acquired upon exercise of stock option grant dated June 2, 2015. Read SEC document |
| December 04, 2024 Filed Dec 5, 2024 17:41 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001064900-24-000002 · primary_doc.xml · derivative · entry 1 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-12-04 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on December 4, 2025. Read SEC document |
| November 25, 2024 Filed Nov 25, 2024 22:09 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | Disposition to issuerStock Option (Right to Buy) · Derivative | 55,555 | $0.00 Strike: $0.09 | $0.00 |
DisclosureSEC source: 0001064900-24-000001 · primary_doc.xml · derivative · entry 2 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,445 Underlying: Common Stock · 55,555 shares Expires 2025-06-02 Read SEC document |
| November 25, 2024 Filed Nov 25, 2024 22:09 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantCommon Stock | 55,555 | $0.09 | $4,999.95 |
DisclosureSEC source: 0001064900-24-000001 · primary_doc.xml · nonDerivative · entry 1 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,329,022 F1 · kind: 55,555 common stock shares acquired upon exercise of stock option grant dated June 2, 2015. Read SEC document |
| November 28, 2023 Filed Nov 29, 2023 23:44 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001345281-23-000009 · primary_doc.xml · derivative · entry 1 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-11-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on November 28, 2024. Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 20:17 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.09 | $0.00 |
DisclosureSEC source: 0001064900-23-000002 · primary_doc.xml · derivative · entry 6 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 50,000 shares Expires 2025-06-02 Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 20:17 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantCommon Stock | 50,000 | $0.09 | $4,500.00 |
DisclosureSEC source: 0001064900-23-000002 · primary_doc.xml · nonDerivative · entry 2 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,273,467 F4 · date: 50,000 common stock shares acquired upon exercise of stock option grant dated June 2, 2015. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 18:39 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GiftCommon Stock | 50,000 | $0.34 | $17,000.00 |
DisclosureSEC source: 0001064900-23-000001 · primary_doc.xml · nonDerivative · entry 1 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,811,800 F1 · shares: Represents 50,000 common stock shares acquired upon gift from Heidi Kay, successor owner to Edward Gerald Kay of such shares upon transfer of ownership upon death. F2 · price: Closing price of Common Stock on date of gift, May 30, 2023. Read SEC document |
| May 25, 2023 Filed Sep 21, 2023 20:17 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (right to buy) · Derivative | 21,667 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001064900-23-000002 · primary_doc.xml · derivative · entry 5 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · As Co-Executor of the Estate of E Gerald Kay Disclosed balance after: 21,667 Underlying: Common Stock · 21,667 shares Expires 2024-03-20 F1 · date: Date Mrs. Sheppard was appointed Co-Executor of the Estate of E Gerald Kay. F1 · deemedExecutionDate: Date Mrs. Sheppard was appointed Co-Executor of the Estate of E Gerald Kay. Read SEC document |
| May 25, 2023 Filed Sep 21, 2023 20:17 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (right to buy) · Derivative | 66,667 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001064900-23-000002 · primary_doc.xml · derivative · entry 4 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · As Co-Executor of the Estate of E Gerald Kay Disclosed balance after: 66,667 Underlying: Common Stock · 66,667 shares Expires 2024-03-20 F1 · date: Date Mrs. Sheppard was appointed Co-Executor of the Estate of E Gerald Kay. F1 · deemedExecutionDate: Date Mrs. Sheppard was appointed Co-Executor of the Estate of E Gerald Kay. F6 · derivative.exercise_date: 33,334 vested on November 4, 2021, the one year anniversary of the grant date and 33,333 vested on November 4, 2022, the second year anniversary of the grant date. Read SEC document |
| May 25, 2023 Filed Sep 21, 2023 20:17 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001064900-23-000002 · primary_doc.xml · derivative · entry 3 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · As Co-Executor of the Estate of E Gerald Kay Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2024-03-20 F1 · date: Date Mrs. Sheppard was appointed Co-Executor of the Estate of E Gerald Kay. F1 · deemedExecutionDate: Date Mrs. Sheppard was appointed Co-Executor of the Estate of E Gerald Kay. F5 · derivative.exercise_date: 25,000 vested on May 24, 2019 and 41,667 vested each May 24, 2020 and 2021 and 41,666 vested on May 24, 2022. Read SEC document |
| May 25, 2023 Filed Sep 21, 2023 20:17 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantCommon Stock | 3,410,512 | $0.40 | $1,364,204.80 |
DisclosureSEC source: 0001064900-23-000002 · primary_doc.xml · nonDerivative · entry 1 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · As Co-Executor of the Estate of E Gerald Kay and as Trustee of the Emily Sheppard Trust Disclosed balance after: 3,426,212 F1 · date: Date Mrs. Sheppard was appointed Co-Executor of the Estate of E Gerald Kay. F1 · deemedExecutionDate: Date Mrs. Sheppard was appointed Co-Executor of the Estate of E Gerald Kay. F2 · price: Closing price of the Issuer's Common Stock on March 20, 2023, date of transfer into the Estate of E Gerald Kay. F3 · ownership.nature: 3,410,512 as Co-Executor of the Estate of E Gerald Kay and 15,700 as Trustee to the Emily Sheppard Trust. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 23:47 UTC | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001064900-22-000001 · primary_doc.xml · derivative · entry 1 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-11-09 F1 · derivative.exercise_price: The Exercise Price of the Stock Option will be the closing prices of the Issuer's Common Stock on the fifth trading day after the filing of the Issuer's Quarterly Report on Form 10-Q for the period ended September 30, 2022, with the Securities and Exchange Commission. F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on November 9, 2023. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:07 UTC | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001064900-21-000001 · primary_doc.xml · derivative · entry 1 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-11-03 F1 · derivative.exercise_price: The Exercise Price of the Stock Option will be the closing price of the Issuer's Commons Stock five trading days after the filing of the Issuer's Quarterly Report on Form 10-Q for the period ended September 30, 2021, with the Securities and Exchange Commission. F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on November 3, 2022. Read SEC document |
| November 04, 2020 Filed Nov 20, 2020 21:45 UTC | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001345281-20-000004 · primary_doc.xml · derivative · entry 1 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-11-04 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on November 4, 2021. Read SEC document |
| May 24, 2019 Filed May 29, 2019 20:27 UTC | INTEGRATED BIOPHARMA INC inbp.ob · Entity 8227 | GrantStock Options (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001064900-19-000001 · primary_doc.xml · derivative · entry 1 RIVA SHEPPARD · CIK 0001064900 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-05-24 F1 · derivative.exercise_date: The option vests 50% (125,000) on grant date (May 24, 2019) and in three equal annual installments for the remaining 50% (125,000) beginning on May 24, 2020. Read SEC document |
| December 19, 2018 Filed Dec 19, 2018 23:47 UTC Amendment | INTEGRATED BIOPHARMA INC inbp.ob · Entity 8227 | GrantCommon Stock | 50,000 | $0.14 | $7,000.00 |
DisclosureSEC source: 0001064900-18-000002 · primary_doc.xml · nonDerivative · entry 1 RIVA SHEPPARD · CIK 0001064900 · Director · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,423,467 F1 · kind: 50,000 common stock shares acquired upon exercise of stock option grant dated January 23, 2009. Read SEC document |
| December 19, 2018 Filed Dec 19, 2018 22:53 UTC | INTEGRATED BIOPHARMA INC inbp.ob · Entity 8227 | GrantCommon Stock | 50,000 | $0.14 | $7,000.00 |
DisclosureSEC source: 0001064900-18-000001 · primary_doc.xml · nonDerivative · entry 1 RIVA SHEPPARD · CIK 0001064900 · Director · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,173,467 F1 · kind: 50,000 common stock shares acquired upon exercise of stock option grant dated January 23, 2009. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.